Patents Assigned to Yeshiva University
  • Acyclic amine inhibitors of 5-methytioadenosine phosphorylase and nucleosidase
    Patent number: 8383636
    Abstract: The present invention relates to compounds of the general formula (I) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: February 26, 2013
    Assignees: Industrial Research Limited, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Keith Clinch, Gary Brian Evans, Richard Frohlich, Richard Hubert Furneaux, Peter Michael Kelly, Jennifer Mary Mason, Vern L. Schramm, Peter Charles Tyler, Shivall Ashwah Ashwin Gulab
  • SIR2 regulation
    Patent number: 8383653
    Abstract: Compounds are disclosed which inhibit SIR2 base exchange more than deacetylation, thus enhancing SIR2 deacetylation activity. Methods of using the compounds for enhancing SIR2 deacetylation activity and increasing longevity of an organism are also disclosed. Methods for screening for compounds that enhance SIR2 deacetylation activity and increase longevity of an organism are additionally disclosed.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: February 26, 2013
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Vern L. Schramm, Anthony A. Sauve
  • TREATMENT OF TYPE 2 DIABETES, METABOLIC SYNDROME, MYOCARDIAL INJURY AND NEURODEGENERATION WITH HUMANIN AND ANALOGS THEREOF
    Publication number: 20130045916
    Abstract: Provided are methods of using humanin and humanin analogs to treat a mammal exhibiting or at risk for insulin resistance, increase insulin sensitivity in a mammal exhibiting or at risk for insulin resistance, treat type-2 diabetes mellitus, metabolic syndrome, and neurodegeneration, treat and prevent myocardial injury, and determine longevity.
    Type: Application
    Filed: October 9, 2012
    Publication date: February 21, 2013
    Applicants: The Regeants of the University of California, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Nir Barzilai, Pinchas Cohen, Radhika Muzumdar, David Lefer
  • Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
    Patent number: 8377886
    Abstract: Methods are provided for treating and preventing renal disease in a subject by administering a gamma secretase inhibitor or a Notch pathway inhibitor to the subject.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: February 19, 2013
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Katalin Susztak, Bernhard Bielesz, Thiruvur G. Niranjan
  • Lateral Flow Device for Diagnosing Microbial Infections
    Publication number: 20130017561
    Abstract: Fungal infections are difficult to diagnose. The most common filamentous fungal infection, aspergillosis, carries with it a high mortality. Culture of the organism is difficult and obtaining samples, e.g., though a lung biopsy, sometimes causes morbidity. Biomarkers that indicate ‘early’ infection in it development are sought after. One such biomarker is detection of galactomannan (GM), a polysaccharide that is attached to hyphal cell walls and secreted during growth of the organism. Galactomannan is excreted in urine. Disclosed herein is a lateral flow assay comprising monoclonal antibodies that recognize specific residues of Aspergillus fumigates for detecting GM in urine samples to provide a point-of-care detection device to allow for frequent screening and early diagnosis in patients at high risk for infection.
    Type: Application
    Filed: November 23, 2010
    Publication date: January 17, 2013
    Applicants: YESHIVA UNIVERSITY, THE JOHNS HOPKINS UNIVERSITY
    Inventors: Kieren A. Marr, Janet F. Staab, Marta Feldmesser
  • Small molecule inhibitors of BCL6
    Patent number: 8338464
    Abstract: Provided are methods of inhibiting BCL6 repression in a mammalian cell. Also provided are methods of treating cancer in a mammal.
    Type: Grant
    Filed: November 29, 2007
    Date of Patent: December 25, 2012
    Assignees: Albert Einstein College of Medicine of Yeshiva University, University Health Network, University of Maryland, Baltimore
    Inventors: Ari Matthew Melnick, Alexander D. MacKerell, Jr., Gilbert Gerard Privé
  • SELECTIVE BETA-GLUCURONIDASE INHIBITORS AS A TREATMENT FOR SIDE EFFECTS OF CAMPTOTHECIN ANTINEOPLASTIC AGENTS
    Publication number: 20120322797
    Abstract: Compounds, compositions and methods are provided that comprise selective ?-glucuronidase inhibitors for both aerobic and anaerobic bacteria, especially enteric bacteria normally associated with the gastrointestinal tract. The compounds, compositions and methods can be for inhibiting bacterial ?-glucuronidases and for improving efficacy of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds by attenuating the side effects caused by reactivation by bacterial ?-glucuronidases of glucuronidated metabolites of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds.
    Type: Application
    Filed: December 9, 2010
    Publication date: December 20, 2012
    Applicants: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, NORTH CAROLINA CENTRAL UNIVERSITY, ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
    Inventors: Matthew R. Redinbo, Sridhar Mani, Alfred Williams, John Scott, Li-An Yeh, Bret David Wallace, Kimberly Terry Lane
  • Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof
    Patent number: 8333997
    Abstract: The invention provides compositions for releasing nitric oxide (NO) comprising a matrix that encapsulates nitric oxide. Nitric oxide is released when the composition is exposed to an aqueous environment. The invention further provides methods of preparing the compositions and uses of the compositions for treating infections and disorders.
    Type: Grant
    Filed: June 20, 2007
    Date of Patent: December 18, 2012
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Joel M. Friedman, Adam Friedman, Mahantesh S. Navati
  • Antigens targeted by pathogenic AI4 T cells in type 1 diabetes and uses thereof
    Patent number: 8318670
    Abstract: Provided are oligopeptide antigens to AI4-like T cells, and mouse proteins comprising those antigens. The oligopeptide antigens comprise the amino acid sequence XX(I/D/F/L)ENY(I/L)(E/W/Y)(L/M) or VMLENYTHL. Additionally provided are methods for treating a mammal having or at risk for type 1 diabetes using these antigens, or compounds which reduce or eliminate expression of these antigens. Kits comprising these antigens, and methods for determining whether a mammal is at risk for or has type 1 diabetes are also provided.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: November 27, 2012
    Assignees: Albert Einstein College of Medicine of Yeshiva University, The Jackson Laboratory
    Inventors: Teresa P. DiLorenzo, Scott M. Lieberman, David V. Serreze
  • Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof
    Patent number: 8309525
    Abstract: Provided are methods of using humanin and humanin analogs to treat a mammal exhibiting or at risk for insulin resistance, increase insulin sensitivity in a mammal exhibiting or at risk for insulin resistance, treat type-2 diabetes mellitus, metabolic syndrome, and neurodegeneration, treat and prevent myocardial injury, and determine longevity.
    Type: Grant
    Filed: May 28, 2008
    Date of Patent: November 13, 2012
    Assignees: Albert Einstein College of Medicine of Yeshiva University, The Regents of the University of California
    Inventors: Nir Barzilai, Pinchas Cohen, Radhika Muzumdar
  • Isolation, gene expression, and chemotherapeutic resistance of motile cancer cells
    Patent number: 8298756
    Abstract: Methods of isolating motile cells of interest from an animal tissue is provided. Also provided are methods of determining mRNA or protein expression of a gene in motile cells of interest from an animal tissue. Additionally, methods of determining whether a cancer in a tissue of a mammal is likely to metastasize are provided. Methods are also provided for inhibiting metastasis of a cancer in a tissue of a mammal. Further provided are methods of determining resistance of a motile cancer cell population in an animal tissue to a chemotherapeutic agent.
    Type: Grant
    Filed: August 4, 2005
    Date of Patent: October 30, 2012
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventor: John S. Condeelis
  • DETECTION OF HEPATIC INSULIN RESISTANCE
    Publication number: 20120269720
    Abstract: Disclosed are methods for determining whether a subject may have hepatic insulin resistance, for diagnosing hepatic insulin resistance, and for assessing the prognosis of a subject with hepatic insulin resistance, comprising determining the level of expression of major facilitator superfamily domain 2 protein (Mfsd2) in a subject's liver, where overexpression of Mfsd2 is indicative of hepatic insulin resistance.
    Type: Application
    Filed: June 16, 2010
    Publication date: October 25, 2012
    Applicant: Albert Einstein College of Medicine of Yeshiva University
    Inventor: David L. Silver
  • Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy
    Patent number: 8283382
    Abstract: The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: October 9, 2012
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Roman Perez-Soler, Yi-He Ling
  • Azetidine analogues of nucleosidase and phosphorylase inhibitors
    Patent number: 8283345
    Abstract: Disclosed are azetidine analogues of nucleosidase and nucleoside phosphorylase inhibitors, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, methods of treating certain diseases using the compounds, processes for preparing the compounds, and intermediates useful in the preparation of the compounds.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: October 9, 2012
    Assignees: Industrial Research Limited, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Gary Brian Evans, Richard Hubert Furneaux, Ben William Greatrex, Vern L. Schramm, Peter Charles Tyler
  • PROSTAGLANDIN TRANSPORTER INHIBITORS AND USES THEREOF
    Publication number: 20120238577
    Abstract: Disclosed are compounds for inhibiting prostaglandin transporter (PGT) activity, pharmaceuticals compositions including the compounds, and methods of treating subjects using the compounds.
    Type: Application
    Filed: September 20, 2010
    Publication date: September 20, 2012
    Applicant: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Victor L. Schuster, Yuling Chi, Andrew S. Wasmuth, Richard S. Pottorf, Gary L. Olson
  • VERSATILE NANOPARTICULATE BIOMATERIAL FOR CONTROLLED DELIVERY AND/OR CONTAINMENT OF THERAPEUTIC AND DIAGNOSTIC MATERIAL
    Publication number: 20120213697
    Abstract: The invention provides compositions for controlled delivery and/or containment of therapeutic and/or diagnostic agents comprising the agent or agents encapsulated by a matrix containing chitosan, polyethylene glycol (PEG) and/or polyvinyl alcohol (PVA), and tetra-methoxy-ortho-silicate (TMOS) or tetra-ethoxy-ortho-silicate (TEOS), as well as methods for preparing the compositions, and uses of the compositions for therapy and imaging.
    Type: Application
    Filed: April 19, 2010
    Publication date: August 23, 2012
    Applicant: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Joel M. Friedman, Adam J. Friedman, George Han, Mahantesh S. Navati, Kevin P. Davies, Moses Tarndie Tar, Alan A. Alfieri, Arturo Casadevall, Ekaterina Dadachova, Helene C. Eisenman, Jasmin N/A, David Spray
  • Assays for S100 inhibitors
    Patent number: 8236791
    Abstract: Provided are methods of determining whether a compound is an inhibitor of an S100 protein. The methods utilize a biosensor that comprises the S100 protein that has a covalently bound fluorescent dye at an amino acid residue of the S100 protein that becomes less exposed to the aqueous solution upon activation of the S100 protein, where the fluorescent dye has decreased fluorescence when exposed to the aqueous solution than when protected from exposure to the aqueous solution. Also provided are methods of treating a subject having metastatic cancer.
    Type: Grant
    Filed: August 10, 2006
    Date of Patent: August 7, 2012
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Anne Reba Bresnick, Sarah Claire Garrett
  • CELL THERAPY FOR TREATMENT OF LIVER FAILURE
    Publication number: 20120189702
    Abstract: Disclosed are methods for treating liver failure in a subject comprising transplanting hepatocytes or stem or progenitor cells in an extrahepatic site in the subject in an amount sufficient to provide liver support and/or induce liver regeneration, where the transplanted hepatocytes or stem or progenitor cells are used along with extracellular matrix-coated microcarriers.
    Type: Application
    Filed: July 16, 2010
    Publication date: July 26, 2012
    Applicant: Albert Einstein College of Medicine of Yeshiva University
    Inventor: Sanjeev Gupta
  • Prostaglandin transporter inhibitors
    Patent number: 8227466
    Abstract: Provided are methods of inhibiting prostaglandin transporter (PGT) activity in mammals. Also provided are methods of determining whether a test compound is an inhibitor of a prostaglandin transporter. Additionally provided are compounds that inhibit prostaglandin transporter activity, and pharmaceutical compositions of those compounds. Methods of inhibiting COX-2 in a mammal are also provided. Additionally, methods of treating pain or inflammation in a mammal are provided.
    Type: Grant
    Filed: May 15, 2007
    Date of Patent: July 24, 2012
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Victor L. Schuster, Yuling Chi, Young-Tae Chang, Jaeki Min
  • ASSAY FOR INHIBITORS OF SUMO AND SUMO-TARGETED UBIQUITIN LIGASE PATHWAY
    Publication number: 20120171707
    Abstract: The present invention provides a method for determining a putative agent that inhibits the SUMO or the SUMO-targeted ubiquitin ligase pathway comprising the steps of contacting mutant MOT1 cells with the putative agent under conditions (1) permitting mutant MOT1 cell growth in the presence of a SUMO or SUMO-targeted ubiquitin ligase pathway inhibitor and (2) not permitting mutant MOT1 cell growth in the absence of a SUMO or SUMO-targeted ubiquitin ligase pathway inhibitor, and measuring cell growth.
    Type: Application
    Filed: August 13, 2010
    Publication date: July 5, 2012
    Applicant: Albert Einstein College of Medicine of Yeshiva University
    Inventor: Gregory Prelich